Currently men with advanced or high risk prostate cancer have heterogenous outcomes, and this test can help better risk-stratify these men after surgery. In our validation study, we found the test was able to re-classify from high-risk to low-risk 60 percent of patients, including high Gleason score patients that, upon clinical follow-up, had exceptionally good outcomes and never needed secondary therapy.
Dr. R. Jeffrey Karnes, Mayo Clinic, MN
Currently in the care of localized prostate cancer, we have been electing to closely survey men with low and very low risk disease and treat those with intermediate and high risk cancers as these men benefit the most from surgery. After prostatectomy, many of these men are at risk for further disease progression (and thus can benefit from additional therapy), but the majority are cured. The availability of genomic information from the tumor tissue after surgery provides valuable information which can help select which men need and which can be spared treatment.
Dr. Ashley Ross, Johns Hopkins Brady Urological Institute, MD
Because they incorporate information from multiple genes at the same time, genomic signatures are the most promising tools we have currently to stratify patient risk and potentially aid in clinical decision making.
Dr. Peter Black, Vancouver Prostate Center, BC
I want to provide my patients with the most comprehensive risk probabilities they will face, and by using Decipher this can be accomplished.
Dr. Ryan Payne, Salina Urology Associates, KS
Decipher helps identify which patients may not need adjuvant treatment, helping them avoid the unwanted complications of treatment, and allowing them to feel confident in their decision not to pursue more treatment.
Dr. Paulos Yohannes, Urology Health Center, NE